NasdaqCM:ESTA

Stock Analysis Report

Establishment Labs Holdings

Executive Summary

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery.

Snowflake

Fundamentals

Limited growth with imperfect balance sheet.

Risks

  • Establishment Labs Holdings has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Establishment Labs Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.6%

ESTA

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

-17.8%

ESTA

9.9%

US Medical Equipment

0.7%

US Market

ESTA underperformed the Medical Equipment industry which returned 9.9% over the past year.

ESTA underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

ESTAIndustryMarket
7 Day-4.6%1.1%-0.6%
30 Day-2.4%1.3%2.9%
90 Day-8.6%3.0%1.3%
1 Year-17.8%-17.8%10.8%9.9%2.9%0.7%
3 Yearn/a70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Establishment Labs Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

1 month ago | Simply Wall St

Trade Alert: The Chairman of the Board Of Establishment Labs Holdings Inc. (NASDAQ:ESTA), Nicholas Lewin, Has Just Spent US$54k Buying Shares

Valuation

Is Establishment Labs Holdings undervalued based on future cash flows and its price relative to the stock market?

7.61x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Establishment Labs Holdings to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Establishment Labs Holdings to establish if it is available at substantial discount.


Price Based on Earnings

Establishment Labs Holdings is loss making, we can't compare its value to the US Medical Equipment industry average.

Establishment Labs Holdings is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Establishment Labs Holdings, we can't assess if its growth is good value.


Price Based on Value of Assets

Establishment Labs Holdings is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Establishment Labs Holdings expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

8.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Establishment Labs Holdings's revenue is expected to grow significantly at over 20% yearly.

Establishment Labs Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.

Establishment Labs Holdings's revenue growth is expected to exceed the United States of America market average.

Unable to compare Establishment Labs Holdings's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Establishment Labs Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Establishment Labs Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Establishment Labs Holdings performed over the past 5 years?

2.3%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Establishment Labs Holdings does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Establishment Labs Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Establishment Labs Holdings's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Establishment Labs Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Establishment Labs Holdings has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Establishment Labs Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Establishment Labs Holdings's financial position?


Financial Position Analysis

Establishment Labs Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Establishment Labs Holdings's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Establishment Labs Holdings's level of debt (44%) compared to net worth is high (greater than 40%).

Unable to establish if Establishment Labs Holdings's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 3.6x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Establishment Labs Holdings has less than a year of cash runway based on current free cash flow.

Establishment Labs Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 22.1% each year.


Next Steps

Dividend

What is Establishment Labs Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Establishment Labs Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Establishment Labs Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Establishment Labs Holdings has not reported any payouts.

Unable to verify if Establishment Labs Holdings's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Establishment Labs Holdings has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Establishment Labs Holdings's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average management tenure


CEO

Juan Jose Chacon Quiros (47yo)

6.7yrs

Tenure

US$483,516

Compensation

Mr. Juan Jose Chacon Quiros founded Establishment Labs, S.A. in 2004 and has been a Chief Executive Officer and Executive Director of Establishment Labs Holdings Inc. since its inception in 2013. Mr. Chaco ...


CEO Compensation Analysis

Juan Jose's remuneration is lower than average for companies of similar size in United States of America.

Juan Jose's compensation has increased whilst company is loss making.


Management Age and Tenure

2.2yrs

Average Tenure

38yo

Average Age

The tenure for the Establishment Labs Holdings management team is about average.


Board Age and Tenure

3.6yrs

Average Tenure

61yo

Average Age

The tenure for the Establishment Labs Holdings board of directors is about average.


Insider Trading

More shares have been bought than sold by Establishment Labs Holdings individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$20,00020 Sep 19
JW Asset Management, LLC
EntityCompany
Shares1,000
Max PriceUS$20.00
BuyUS$20,40026 Aug 19
JW Asset Management, LLC
EntityCompany
Shares1,000
Max PriceUS$20.40
BuyUS$20,00021 Aug 19
JW Asset Management, LLC
EntityCompany
Shares1,000
Max PriceUS$20.00
BuyUS$42,84019 Aug 19
JW Asset Management, LLC
EntityCompany
Shares2,000
Max PriceUS$21.42
BuyUS$54,28919 Aug 19
Nicholas Lewin
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares2,700
Max PriceUS$20.11
BuyUS$66,45012 Aug 19
JW Asset Management, LLC
EntityCompany
Shares3,000
Max PriceUS$22.15
BuyUS$37,95802 Aug 19
JW Asset Management, LLC
EntityCompany
Shares1,500
Max PriceUS$25.31
BuyUS$63,95030 Jul 19
JW Asset Management, LLC
EntityCompany
Shares2,500
Max PriceUS$25.58

Ownership Breakdown


Management Team

  • Juan Jose Chacon Quiros (47yo)

    Founder

    • Tenure: 6.7yrs
    • Compensation: US$483.52k
  • Eddie De Oliveira (37yo)

    Vice President of Sales

    • Tenure: 0yrs
    • Compensation: US$429.33k
  • Renee M. Gaeta (38yo)

    Chief Financial Officer

    • Tenure: 2.2yrs
    • Compensation: US$374.21k
  • Jeremy Livianu (38yo)

    General Counsel

    • Tenure: 1.4yrs
  • Roberto De Mezerville (39yo)

    Chief Technology Officer

    • Tenure: 1.6yrs
  • Salvador Santos Dada (37yo)

    Chief Operating Officer

    • Tenure: 3.6yrs
    • Compensation: US$234.23k

Board Members

  • Dennis Condon (70yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$21.41k
  • David Hung (61yo)

    Director

    • Tenure: 3.6yrs
    • Compensation: US$19.59k
  • Lisa Colleran (61yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$24.60k
  • Hall Gersh (60yo)

    Director

    • Tenure: 0.3yrs
  • Nick Lewin (41yo)

    Chairman of the Board

    • Tenure: 1.8yrs
    • Compensation: US$4.53m
  • Juan Jose Chacon Quiros (47yo)

    Founder

    • Tenure: 6.7yrs
    • Compensation: US$483.52k
  • Ed Schutter (68yo)

    Director

    • Tenure: 3.7yrs
    • Compensation: US$19.36k
  • Marcos Sforza

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Dennis Hammond

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Niamh Corduff

    Member of Medical Advisory Board

    • Tenure: 0yrs

Company Information

Establishment Labs Holdings Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Establishment Labs Holdings Inc.
  • Ticker: ESTA
  • Exchange: NasdaqCM
  • Founded: 2004
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$409.587m
  • Shares outstanding: 20.50m
  • Website: https://www.establishmentlabs.com

Number of Employees


Location

  • Establishment Labs Holdings Inc.
  • Buildings B15 and 25
  • Coyol Free Zone
  • Alajuela
  • Costa Rica

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ESTANasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJul 2018
3DB (Deutsche Boerse AG)YesCommon SharesDEEURJul 2018

Biography

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silic ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:35
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.